Myriad Genetics, Inc.
MYGN
F
|
$19.19
-1.84%
-1.88%
570K
|
Health Technology
(0.0% 1d) (-11.4% 1m) (-14.0% 1y) (0.0% 2d) (0.0% 3d) (-5.4% 7d) (3.82% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 1,724,699,062
http://www.myriad.com
Sec Filling | Patents | 2700 employees
(US) Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
molecular diagnostics genetic diagnostics information technology
add to watch list Paper trade email alert is off
Press-releases
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: 0.44%
H: 3.39%
C: 2.5%
depression genesight research for
Companion Diagnostics Market Worth $13.6 billion | MarketsandMarkets™
Published: 2024-04-05 (Crawled : 14:30) - prnewswire.com
TMO | $557.87 -1.3% 0.0% 1M
|
Health Technology
|
| O: -1.7%
H: 2.39%
C: 1.62%
A | $140.22 -0.36% 0.0% 1.5M
|
Health Technology
|
| O: 2.01%
H: 0.92%
C: -0.04%
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: -0.64%
H: 2.19%
C: 0.85%
ILMN | $121.18 -4.64% -4.86% 1.6M
|
Health Technology
|
| O: -0.75%
H: 3.52%
C: 2.16%
ICLR | $299.21 -2.22% -2.27% 380K
|
Health Technology
|
| O: 0.31%
H: 2.54%
C: 1.49%
companion diagnostics market
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Published: 2024-03-22 (Crawled : 02:00) - globenewswire.com
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: 0.13%
H: 0.69%
C: -0.4%
patent disease granted molecular
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Published: 2024-03-20 (Crawled : 20:00) - globenewswire.com
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: 0.72%
H: 1.43%
C: -0.45%
sneakpeek patent device granted
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
Published: 2024-02-27 (Crawled : 21:00) - globenewswire.com
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: -1.06%
H: 2.15%
C: -7.05%
million revenue financial
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
Published: 2024-02-27 (Crawled : 14:00) - globenewswire.com
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: 0.31%
H: 3.26%
C: 2.17%
japan hospital cancer
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Published: 2024-02-21 (Crawled : 21:00) - globenewswire.com
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: 0.35%
H: 2.35%
C: 0.48%
year financial results
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: -0.68%
H: 1.15%
C: -0.77%
health medical
Clinical Biomarkers Market Analysis and Forecast, 2023-2033 - Cancer Biomarkers to Witness the Highest Growth between 2023 and 2033
Published: 2024-02-13 (Crawled : 03:00) - prnewswire.com
TMO | $557.87 -1.3% 0.0% 1M
|
Health Technology
|
| O: -0.99%
H: 0.88%
C: -0.52%
DGX | $128.64 0.09% 0.0% 700K
|
Health Services
|
| O: 0.01%
H: 0.55%
C: -1.66%
QGEN | $39.67 -1.27% 0.0% 550K
|
Health Technology
|
| O: -1.64%
H: 0.58%
C: -0.56%
BIO | $300.41 -0.01% 0.0% 170K
|
Health Technology
|
| O: -1.32%
H: 0.37%
C: -1.83%
BDX | $234.72 -0.19% 0.0% 830K
|
Health Technology
|
| O: 0.04%
H: 0.72%
C: -1.81%
A | $140.22 -0.36% 0.0% 1.5M
|
Health Technology
|
| O: -2.03%
H: 1.0%
C: -0.44%
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: 0.0%
QGEN | $39.67 -1.27% 0.0% 550K
|
Health Technology
|
| O: -1.64%
H: 0.58%
C: -0.56%
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: -3.99%
H: 1.49%
C: -3.71%
ILMN | $121.18 -4.64% -4.86% 1.6M
|
Health Technology
|
| O: -2.48%
H: 1.08%
C: -2.01%
CNTG | $0.5555 -11.21% 87K
|
Commercial Services
|
| O: 2.59%
H: 0.0%
C: -11.11%
cancer biomarkers growth market
Companion Diagnostics (CDx) Market Report 2024-2034 - High Capital Investment and Low Cost-benefit Ratio to Challenge Industry Growth
Published: 2024-02-09 (Crawled : 12:00) - prnewswire.com
TMO | $557.87 -1.3% 0.0% 1M
|
Health Technology
|
| O: -0.23%
H: 0.82%
C: 0.2%
DHR | $239.66 -0.12% 0.0% 2.7M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: -0.24%
A | $140.22 -0.36% 0.0% 1.5M
|
Health Technology
|
| O: 1.22%
H: 0.0%
C: 0.0%
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
MYGN F | $19.19 -1.84% -1.88% 570K
|
Health Technology
|
| O: 0.32%
H: 1.98%
C: -0.86%
ILMN | $121.18 -4.64% -4.86% 1.6M
|
Health Technology
|
| O: 0.29%
H: 2.75%
C: -4.11%
report companion diagnostics growth market
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Last 48 Hours Insiders Buying
RMCF | $3.56 -7.2% 7.1K
|
Consumer Non-Durables
|
20:10